Across TCGA pan-cancer cohorts, BTBD18 Mutation is linked to patient survival in 1 of 34 cancer types, making it a survival-associated BTBD18 data layer compared with 21 for mass-spec protein.
The strongest signal is observed in small cell lung cancer (SCLC), where higher BTBD18 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated BTBD18 expression acts as an unfavorable survival marker.
SCLC are the cancer types where BTBD18 Mutation most reproducibly stratifies survival.